CLAIMS

1. Mixed micelles or micro-aggregates for inducing an immune response containing at least :

- a first lipopeptide comprising at least one CTL antigenic determinant and at least one lipid unit, and

- a second lipopeptide comprising at least one helper T antigenic determinant and at least one lipid unit, which may be of a different type from the first lipopeptide unit.

2. Micelles or micro-aggregates according to claim 1, characterized in that the lipopeptides independently comprise one or more C_4-C_{18} lipid units.

3. Micelles or micro-aggregates according to one of claims 1and 2, characterized in that the lipopeptides independently comprise one or two C_4-C_{18} lipid chains linked by a covalent bond to one or two amino acids of the peptide part.

4. Micelles or micro-aggregates according to one of claims 1 to 3, characterized in that the lipid units of the lipopeptides are composed of two palmitic acid chains linked to the NH_2 groups of a lysine.

5. Micelles or micro-aggregates according to one of claims 1 to 4, characterized in that the lipid units of the lipopeptides independently comprise a residue of palmitic acid, 2-aminohexadecanoic acid, oleic acid, linoleic acid, linolenic acid, pimelautide, trimexautide, or a derivative of cholesterol.

6. Micelles or micro-aggregates according to one of claims 1 to 5, characterized in that the non-lipid part of the lipopeptides, comprising the antigenic determinants, comprises between 10 and 100, and preferably between 10 and 50 amino acids.

7. Micelles or micro-aggregates according to one of claims 1 to 6, characterized in that the helper T antigenic determinant is a multivalent antigenic determinant.

8. Micelles or micro-aggregates according to one of claims 1 to 7, characterized in that the helper T antigenic determinant is the peptide 830-843 of the tetanus toxin with the following sequence:

QYIKANSKFIGITE

9. Micelles or micro-aggregates according to one of claims 1 to 7, characterized in that the helper T antigenic determinant is the antigenic determinant of hemagglutinin or the PADRE antigenic determinant.

10. Micelles or micro-aggregates according to one of claims 1 to 9, characterized in that the lipopeptides comprise at least one CTL antigenic determinant of a specific protein of melanoma, of a protein from HIV, from HBV, from papillomavirus, or protein p53, or a specific protein of *Plasmodium falciparum*.

11. Micelles or micro-aggregates according to one of claims 1 to 10, characterized in that they comprise the following lipopeptides:

GAG 17	E K I R L R P G G K K K Y K L K H I V K(Pam)-NH_2
GAG 253	N P P I P V G E I Y K R W I I L G L N K I V R M Y S P T S I L D K(Pam)-NH_2
POL 325	A I F Q S S M T K I L E P F R K Q N P D I V I Y Q Y M D D L Y K(Pam)-NH_2
NEF 66	V G F P V T P Q V P L R P M T Y K A A V D L S H F L K E K G G L K(Pam)-NH_2
NEF 116	H T Q G Y F P D W Q N Y T P G P G V R Y P L T F G W L Y K L K(Pam)-NH_2
TT	Ac-Q Y I K A N S K F I G I T E L K K K(Pam)-NH_2

12. Micelles or micro-aggregates according to one of claims 1 to 10, characterized in that they comprise the following lipopeptides:

LSA3 CT1	L L S N I E E P K E N I I D N L L N N I K(Pam)-NH_2
LSA3 NRI	Ac-D E L F N E L L N S V D V N G E V K E N I L E E S Q K(Pam)-NH_2
LSA3 NRII	Ac-L E E S Q V N D D I F N S L V K S V Q Q E Q Q H N V K(Pam)-NH_2
LSA3 RE	K(Pam) V E S V A P S V E E S V A P S V E E S V A E N V E E S V A E N V-NH_2

13. Use of micelles or micro-aggregates according to one of claims 1 to 12 for the production of a drug or a vaccine for inducing a specific immune response.

14. Use of micelles or micro-aggregates according to one of claims 1 to 12 for the production of a drug or a vaccine for inducing a specific immune response against HIV, HBV, papillomavirus, p53, melanoma or malaria induced by *Plasmodium falciparum*.

15. Pharmaceutical composition characterized in that it comprises a pharmacologically effective dose of micelles or micro-aggregates according to one of claims 1 to 12 and pharmaceutically compatible vehicles.

16. Drug or vaccine characterized in that it comprises micelles or micro-aggregates according to one of claims 1 to 12.

17. Method for producing micelles or micro-aggregates according to one of claims 1 to 12, comprising the following steps:

- dispersion of each of the constituent lipopeptides in a solution of concentrated acetic acid of about 80% concentration then
- mixing the solutions thus obtained.

18. Method according to claim 17 characterized in that the production of a dispersion of the lipopeptides dissolved in acetic acid is controlled by the two-dimensional nuclear magnetic resonance method.

19. Method for inducing an immune response against a particular antigen comprising at least the administration of micelles or micro-aggregates according to one of claims 1 to 12 to an individual for whom such a response is desired.

20 Method of immunization against a pathogenic agent comprising the administration of micelles or micro-aggregates according to one of claims 1 to 12 to an individual for whom such an immunization is sought.

21. Method according to one of claims 19 and 20, characterized in that the pathogenic agent is HIV, HBV, papillomavirus, melanoma or *Plasmodium falciparum*, and the antigen an antigen of one of these agents, or p53.